RxDoctor Payments Data

Elena Levy, PA

Physician Assistant · Fresh Meadows, NYNPI 1629179569

Payments from drug & device makers

$5,362in general payments, 2019–2025

Across 144 payments — averaging $37.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$2K
  • Regeneron Healthcare Solutions, Inc.$771
  • GSK$576
  • Optinose US, Inc.$556
  • Alk-abello, Inc$292
  • ARS Pharmaceuticals Operations, Inc.$145
  • plus $992 from 12 others

What the payments were for

  • Food & beverage$5,30999%
  • Education$531%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,362 in reported general payments places this provider in the 90th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$187,649
Medicare patients
453
Services billed
2,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Azelastine Hcl707$15,024
XhanceFluticasone Propionate20$12,348
ViibrydVilazodone Hcl22$7,515
Fluticasone Propionate564$6,265
Mometasone Furoate176$3,356
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth14$1,672
Ipratropium Bromide67$1,497
Neomycin-Polymyxin-HcNeomycin/Polymyxin B/Hydrocort16$699
Escitalopram Oxalate42$405
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav31$393
Montelukast Sodium37$359
Mupirocin47$276
Trazodone Hcl29$258
Duloxetine Hcl29$256
Methylprednisolone28$224

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Optinose US, Inc.Xhance$556$12,34820 claims
AbbVieViibryd$125$7,51522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Fresh Meadows

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →